TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03863483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab will be administered intravenously at a fixed dose of 200 milligrams (mg) on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel 75 milligrams per square meter (mg/m\^2) will be administered intravenously on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75 milligrams per square meter (mg/m\^2) will be administered intravenously on Day 1 of each 21-day cycle.
Study: NCT03863483

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed 500 mg/m\^2 will be administered intravenously on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed 500 mg/m\^2 will be administered intravenously on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride injection as placebo will be administered intravenously at a fixed dose of 100 milliliters (mL) on Day 1 of each 21-day cycle.
Study: NCT04003584

Intervention type: PROCEDURE
Intervention: Coronary bypass surgery
Description: Reviewed postoperative coronary bypass patients and compared postoperative pain levels

Intervention type: PROCEDURE
Intervention: Coronary bypass surgery
Description: Reviewed postoperative coronary bypass patients and compared postoperative pain levels
Study: NCT03452072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.25% Timolol gel with paraffin gauze dressings
Description: Timolol 0.25% gel will be applied to wound bed immediately after surgery before dressing is applied. Starting the day after surgery: each day, the patient will cleanse the surgical site, apply 0.25% topical timolol gel (1 drop = 0.1ml for each cm2 of wound area), and re-cover wound with clean dressing

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vaseline dressing
Description: Vaseline will be applied to wound bed immediately after surgery before dressing is applied. Starting the day after surgery: each day, the patient will cleanse the surgical site, apply Vaseline, and re-cover wound with clean dressing
Study: NCT03606421

Intervention type: RADIATION
Intervention: SRS and neurocognitive assessments
Description: Patients will be assessed for cerebral blood flow and their neurocognitive function based on a series of neurocognitive tests and questionnaires.

Intervention type: RADIATION
Intervention: WBRT and neurocognitive assessments
Description: Patients will be assessed for cerebral blood flow and their neurocognitive function based on a series of neurocognitive tests and questionnaires.
Study: NCT04560465

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tranexamic acid
Description: intravenous perioperative tranexamic acid was added into infusion of normal saline for the cases while placebo of intravenous water for injection was added into normal saline perioperatively for control

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: intravenous perioperative tranexamic acid was added into infusion of normal saline for the cases while placebo of intravenous water for injection was added into normal saline perioperatively for control
Study: NCT03348917

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 7.5% Povidone-Iodine [PVP-I]
Description: Betadine® 7.5% skin cleanser (PVP-I 7.5%)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 7.5% Povidone-Iodine [PVP-I]
Description: Betadine® 7.5% skin cleanser (PVP-I 7.5%)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 7.5% Povidone-Iodine [PVP-I]
Description: Betadine® 7.5% skin cleanser (PVP-I 7.5%)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 4% chlorhexidine skin cleanser
Description: Unity antiseptic hand wash (no alcohol)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 4% chlorhexidine skin cleanser
Description: Unity antiseptic hand wash (no alcohol)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 4% chlorhexidine skin cleanser
Description: Unity antiseptic hand wash (no alcohol)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Plain non antibacterial soap
Description: Guardian gel hand wash (not medicated),

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Plain non antibacterial soap
Description: Guardian gel hand wash (not medicated),

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Plain non antibacterial soap
Description: Guardian gel hand wash (not medicated),
Study: NCT02932332

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low-flow Air
Description: Two level air flow (high and low) will be delivered by Optiflow in an identical manner to oxygen air flows, except that researchers will use pressurized air instead of oxygen. LFOx and LFAir will be provided at 2 L/min using a nasal cannula identical to that used for high-flow devices.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Low-flow Air
Description: Two level air flow (high and low) will be delivered by Optiflow in an identical manner to oxygen air flows, except that researchers will use pressurized air instead of oxygen. LFOx and LFAir will be provided at 2 L/min using a nasal cannula identical to that used for high-flow devices.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low-flow Air
Description: Two level air flow (high and low) will be delivered by Optiflow in an identical manner to oxygen air flows, except that researchers will use pressurized air instead of oxygen. LFOx and LFAir will be provided at 2 L/min using a nasal cannula identical to that used for high-flow devices.
Study: NCT04910763

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Exercise
Description: Increasing strength and fitness and thereby influencing hormones and perceptions involved in appetite regulation.
Study: NCT03611322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide, 0.25 mg
Description: Semaglutide will be administered subcutaneously (s.c., under the skin) on day 1 and 8 in the morning after an overnight fast of at least 8 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide, 0.25 mg
Description: Semaglutide will be administered subcutaneously (s.c., under the skin) on day 1 and 8 in the morning after an overnight fast of at least 8 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide, 0.5 mg
Description: Semaglutide will be administered s.c. (under the skin) on day 15 and 22 in the morning after an overnight fast of at least 8 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide, 0.5 mg
Description: Semaglutide will be administered s.c. (under the skin) on day 15 and 22 in the morning after an overnight fast of at least 8 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide, 1.0 mg
Description: Semaglutide will be administered s.c. (under the skin) on day 29 in the morning after an overnight fast of at least 8 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide, 1.0 mg
Description: Semaglutide will be administered s.c. (under the skin) on day 29 in the morning after an overnight fast of at least 8 hours

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DV3372
Description: DV3372 device will be used for administration of semaglutide

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PDS290 pen-injector
Description: PDS290 pen-injector will be used for administration of semaglutide
Study: NCT01560897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral C13
Description: Ingestion of C13 and follow up of the ureogenesis
Study: NCT00256087

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic Lactobacillus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic Lactobacillus
Study: NCT03752983

Intervention type: DIAGNOSTIC_TEST
Intervention: blood samples
Description: blood samples

Intervention type: DIAGNOSTIC_TEST
Intervention: blood samples
Description: blood samples
Study: NCT05045131

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Left atrial combined pulmonary vein isolation and posterior wall isolation
Study: NCT04425616

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: At least one and up to three supervised sessions per week including:~* aerobic exercise at a rating of perceived exertion of 11-14 (6-20 scale) accumulating 20 minutes per session~* resistance exercise of 8-10 exercises for 2x 8-15 repetitions performed in a controlled manner and covering the whole body~* Range of motion exercise performed through pain free range of motion covering the whole body to be maintained in good alignment for 10-30 seconds, with some movements held for a second set of 10-30 seconds if stiff

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychological and Behaviour Change Support
Description: Instructors will be trained in Healthy Conversation Skills (HCS), Making Every Contact Count (MECC) or equivalent. This will enable them to deliver brief participant centred empowering interventions informed by social cognitive theory. This skill set will be used to support participants in adopting and maintaining the prescribed exercise and diet programme as well as adopting and practicing strategies to self-manage psychological well-being. Participants will be given the option to be provided with a SMARTER goal setting sheet to assist with goal planning. Applicable standardised psychological support resources will be made available to the participants though the Macmillan resource repository that they can access online or in alternative format as necessary, for example relaxation and mindfulness exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition
Description: Instructors will receive training in generic nutritional principles in line with recommendations from World Cancer Research Fund (WCRF) and British Dietetic Association, and will work with participant to review own diet and eating habits against WCRF recommendations to enable goal setting and identify links to existing resources reputable websites, outputs and on-line forums. These would include: principles of healthy eating ('eat well' advice), weight management, symptom management, prehab advice before treatment starts, rehab advice during and after treatment. The participant will be asked if they are eating and drinking well or have any concerns at the beginning of each exercise session. Further support will be provided to instructors to address participant concerns or requests for additional information.
Study: NCT03649113

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sclerotherapy arm
Description: The liver mass will be punctured under guidance of ultrasonography with a 20- or 22-gauge Chiba needle. Contrast medium will be injected under fluoroscopy guidance to assess any possible communication with the biliary tree and to evaluate the amount of sclerosing agent which could be safely injected. Then, the mixture of Bleomycin (Bleocin-S; Korea United Pharm Inc., South Korea) and Lipiodol (Ultra-Fluid, Guerbet, France) will be slowly injected under continuous guidance of fluoroscopy. No more than 45 units of Bleomycin and 15 cc of Lipiodol will be injected in a single session.
Study: NCT01086982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide acetate LAR
Description: 30 mg, single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sandostatin LAR ® (octreotide acetate LAR) 30 MG
Description: 30 mg, single dose
Study: NCT02634541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Biologic drug
Study: NCT04177355

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BG505 SOSIP.664 gp140
Description: Administered by IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BG505 SOSIP.664 gp140
Description: Administered by IM injection
Study: NCT01898637

Intervention type: OTHER
Group type: OTHER
Intervention: Augmented pulse oximetry using incentive spirometer.
Description: Augmented pulse oximetry using incentive spirometer.
Study: NCT02634541

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PET/CT imaging
Description: PET/CT imaging

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PET/CT imaging
Description: PET/CT imaging
Study: NCT02578589

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Plica resection vs conservative treatment
Description: Plica resection vs conservative treatment
Study: NCT02398617

Intervention type: OTHER
Group type: OTHER
Intervention: Decision Making Intervention
Description: At their regularly scheduled admission follow-up visit with seven days of discharge, participants will be asked to bring their medical decision maker and participate in a semi-structured supplemental palliative care/education session facilitated by a heart failure nurse practitioner trained in palliative care discussions. Domains included in the intervention will include disease literacy and understanding, goals of care, legal issues for patients with terminal illness, symptom management, health-related quality of life, caregiver burden, patient autonomy, healthcare utilization, and establishment of end-of-life plans.
Study: NCT02531152

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR366234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR366234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR366234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR366234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR366234
Study: NCT04177355

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by IM injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by IM injection
Study: NCT01939171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Study: NCT04177355

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by IM injection
Study: NCT00256087

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Lactose Powder
Study: NCT01594138

Intervention type: OTHER
Intervention: Standardized questionnaires and a ubiquitous questionnaire
Description: Columbia Suicide Severity Rating Scale, Suicidal Ideation Questionnaire,Peabody Caregiver Background Form,CCHMC Suicide History Form,and ubiquitous questionnaire(UQ ver.2011)
Study: NCT04177355

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by IM injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by IM injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by IM injection
Study: NCT04177355

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by IM injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3M-052-AF
Description: Administered by IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3M-052-AF
Description: Administered by IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3M-052-AF
Description: Administered by IM injection
Study: NCT02257164

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral nerve block
Description: 2 mg/ml

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: obturator nerve block

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intraarticular injection
Study: NCT00720421

Intervention type: DRUG
Group type: OTHER
Intervention: AZD7325
Description: AZD7325 10 mg oral 2 capsules

Intervention type: DRUG
Group type: OTHER
Intervention: AZD7325
Description: AZD7325 10 mg oral 2 capsules

Intervention type: DRUG
Group type: OTHER
Intervention: AZD7325
Description: AZD7325 10 mg oral 2 capsules

Intervention type: DRUG
Group type: OTHER
Intervention: AZD7325
Description: AZD7325 10 mg oral 2 capsules

Intervention type: DRUG
Group type: OTHER
Intervention: AZD7325
Description: AZD7325 1 mg oral 2 capsules

Intervention type: DRUG
Group type: OTHER
Intervention: AZD7325
Description: AZD7325 1 mg oral 2 capsules

Intervention type: DRUG
Group type: OTHER
Intervention: AZD7325
Description: AZD7325 1 mg oral 2 capsules
Study: NCT04177355

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3M-052-AF
Description: Administered by IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3M-052-AF
Description: Administered by IM injection
Study: NCT03472755

Intervention type: OTHER
Group type: OTHER
Intervention: The posterolateral approach
Description: The posterolateral approach was used for implantation among patients in lateral position. This approach goes through the gluteus maximus, the piriformis and superior gemeli muscles are detached and later reattached to bone

Intervention type: OTHER
Group type: OTHER
Intervention: Direct anterior technique
Description: patients were fixed in a supine position, a small entry incision was made in the vessel free interval between the tensor fasciae latae and the sartorius muscles and the prosthesis socket were put in place. Via a second dorsal incision, after releasing the external rotators, the prosthesis stem and ball were implanted and the two parts of the prosthesis were attached
Study: NCT04650386

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychosocial support determined by adaptive treatment algorithm
Description: Participants assigned to the adaptive intervention condition will be scheduled for buprenorphine medication management appointments according to the clinic protocol described above for TAU. The adjunctive psychosocial treatment that participants in this condition receive are (1) CBT delivered by behavioral health specialists and/or (2) peer support delivered by certified recovery specialist. The active intervention period will span 3 months post-study entry. Participants will continue to receive TAU following the active intervention period.
Study: NCT04101968

Intervention type: DIAGNOSTIC_TEST
Intervention: PET scan
Description: 3 PET scans to analyze the dopamine metabolism, acetylcholine and tau protein deposition in the brain.

Intervention type: DIAGNOSTIC_TEST
Intervention: PET scan
Description: 3 PET scans to analyze the dopamine metabolism, acetylcholine and tau protein deposition in the brain.

Intervention type: DIAGNOSTIC_TEST
Intervention: neuroQWERTY
Description: Analysis of free-text typing in a computer and/or a touch-screen device.

Intervention type: DIAGNOSTIC_TEST
Intervention: neuroQWERTY
Description: Analysis of free-text typing in a computer and/or a touch-screen device.
Study: NCT04177355

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CpG 1018
Description: Administered by IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GLA-LSQ
Description: Administered by IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alum (Aluminum Hydroxide Suspension)
Description: Administered by IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alum (Aluminum Hydroxide Suspension)
Description: Administered by IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alum (Aluminum Hydroxide Suspension)
Description: Administered by IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alum (Aluminum Hydroxide Suspension)
Description: Administered by IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alum (Aluminum Hydroxide Suspension)
Description: Administered by IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alum (Aluminum Hydroxide Suspension)
Description: Administered by IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alum (Aluminum Hydroxide Suspension)
Description: Administered by IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trimer 4571
Description: Administered by IM injection
Study: NCT04155398

Intervention type: PROCEDURE
Intervention: EUS elastography
Description: A forward view radial echoendoscope or a forward oblique view linear echoendoscope would be used to perform focused luminal examination of varices and EUS elastography for measurement of liver stiffness and spleen stiffness.
Study: NCT01068184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6553
Description: Single or multiple oral dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single or multiple oral dose
Study: NCT03547427

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Basal insulin alone
Description: A study insulin pump containing lispro insulin will be programmed to deliver basal lispro insulin at according to the subject's normal basal profile. The carbohydrate ratio(s) and insulin sensitivity factor(s) will be programmed per the subject's usual home parameters.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Basal insulin alone
Description: A study insulin pump containing lispro insulin will be programmed to deliver basal lispro insulin at according to the subject's normal basal profile. The carbohydrate ratio(s) and insulin sensitivity factor(s) will be programmed per the subject's usual home parameters.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Basal pramlintide and reduced basal insulin
Description: A study insulin pump containing pramlintide will be programmed to deliver pramlintide at 6:1 pramlintide:insulin ratio. Simultaneously, a study insulin pump containing lispro insulin will be programmed to deliver basal lispro insulin at \~25% reduced rate from the subject's normal basal profile. The carbohydrate ratio(s) and insulin sensitivity factor(s) will be programmed per the subject's usual home parameters.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Basal pramlintide and reduced basal insulin
Description: A study insulin pump containing pramlintide will be programmed to deliver pramlintide at 6:1 pramlintide:insulin ratio. Simultaneously, a study insulin pump containing lispro insulin will be programmed to deliver basal lispro insulin at \~25% reduced rate from the subject's normal basal profile. The carbohydrate ratio(s) and insulin sensitivity factor(s) will be programmed per the subject's usual home parameters.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CGM
Description: Subjects will be instructed to initiate a Continuous Glucose Monitor (CGM) session 2-3 days prior to both the experimental and control CRU admissions.